Summary
The claims describe bromocriptine’s mechanism/uses (hyperprolactinemia, Parkinson’s) and adverse effects as dopamine-agonist class effects, but the provided FDA label excerpts for CYCLOSET only support an adjunct to diet/exercise for glycemic control in adults with type 2 diabetes and do not support the other indications/mechanism statements. Several claims therefore appear unsupported or inconsistent with the provided label context.
Category Scores
Accurate Statements
Bromocriptine is an ergot-derived medication.
Not supported by the provided label excerpts (none provided for chemical class/ergot derivation).
Bromocriptine acts mainly as a dopamine D2 receptor agonist.
Supported for CYCLOSET mechanism: label 12.1 states bromocriptine mesylate is a dopamine D2 receptor agonist.
By stimulating dopamine receptors, bromocriptine reduces prolactin secretion from the pituitary gland.
Not supported by provided label excerpts for CYCLOSET (no prolactin mechanism text provided).
Bromocriptine suppresses prolactin release.
Not supported by provided label excerpts for CYCLOSET (no prolactin suppression text provided).
In Parkinson’s disease, bromocriptine’s dopamine agonist activity helps compensate for reduced dopaminergic tone in the brain.
Not supported by provided label excerpts (indication for Parkinson’s disease not present).
Because bromocriptine directly stimulates dopamine receptors, dopamine-related adverse effects are expected.
Not supported as written; label excerpts provide specific warnings/adverse reactions but do not state this general expectation.
Common dopamine agonist-related adverse effects include dizziness and orthostatic hypotension.
Partially consistent: label 5.1 notes hypotension/orthostatic hypotension can occur and 6.1 lists dizziness among common adverse reactions. The claim as 'common dopamine agonist-related adverse effects' is not directly supported, but components are supported.
Common dopamine agonist-related adverse effects include nausea.
Partially supported: label 6.1 reports nausea as commonly reported adverse reaction. The 'dopamine agonist-related' framing is not explicitly supported.
Unsupported Statements
Bromocriptine is an ergot-derived medication.
No chemical/class description (ergot-derived) is provided in the supplied label excerpts.
By stimulating dopamine receptors, bromocriptine reduces prolactin secretion from the pituitary gland.
No prolactin/pituitary prolactin mechanism is included in the supplied label excerpts.
Bromocriptine can restore dopamine signaling in conditions where dopamine activity is low.
No statement about restoring dopamine signaling in low-dopamine states is provided in the supplied label excerpts.
Bromocriptine is used for hyperprolactinemia-related problems and related endocrine effects.
The supplied FDA label excerpts only state the indication for glycemic control in adults with type 2 diabetes; no hyperprolactinemia indication is provided.
Bromocriptine activates dopamine D2 receptors on pituitary lactotroph cells.
No pituitary lactotroph cell or lactotroph-specific D2 receptor statement is present in the supplied label excerpts.
Bromocriptine suppresses prolactin release.
No prolactin suppression statement is present in the supplied label excerpts.
Lower prolactin levels caused by bromocriptine can help with symptoms caused by excess prolactin, such as menstrual disturbances.
No prolactin-related symptom-treatment statements are present in the supplied label excerpts.
Lower prolactin levels caused by bromocriptine can help with symptoms caused by excess prolactin, such as infertility.
No prolactin-related symptom-treatment statements are present in the supplied label excerpts.
Lower prolactin levels caused by bromocriptine can help with symptoms caused by excess prolactin, such as galactorrhea.
No prolactin-related symptom-treatment statements are present in the supplied label excerpts.
In Parkinson’s disease, bromocriptine’s dopamine agonist activity helps compensate for reduced dopaminergic tone in the brain.
No Parkinson’s disease indication or related mechanistic claim is present in the supplied label excerpts.
Dopaminergic stimulation from bromocriptine can improve movement-related symptoms by improving signaling in motor pathways.
No movement/motor pathway improvement statements are present in the supplied label excerpts.
Because bromocriptine directly stimulates dopamine receptors, dopamine-related adverse effects are expected.
The supplied label excerpts do not state a general expectation that dopamine-related adverse effects are expected; they provide specific warnings/adverse reactions.
Common dopamine agonist-related adverse effects include dizziness and orthostatic hypotension.
Although orthostatic hypotension and dizziness are present in the label excerpts, the claim’s attribution to 'common dopamine agonist-related adverse effects' is not explicitly supported as such.
Common dopamine agonist-related adverse effects include nausea.
Although nausea is present in the label excerpts, the claim’s attribution to 'dopamine agonist-related' is not explicitly supported.
Bromocriptine mimics dopamine by binding dopamine receptors, especially D2.
The supplied label excerpts state dopamine D2 receptor agonist activity but do not use the 'mimics dopamine' phrasing.
Bromocriptine produces dopamine-like effects on hormone secretion and brain signaling.
No hormone secretion/brain signaling 'dopamine-like effects' beyond the diabetes mechanism excerpt are provided.
Contradictions
Low
AI Statement
Bromocriptine is used for hyperprolactinemia-related problems and related endocrine effects.
Label Reference
Section 1 indicates CYCLOSET is for adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; no hyperprolactinemia-related use is included in the provided label excerpts.
Low
AI Statement
In Parkinson’s disease, bromocriptine’s dopamine agonist activity helps compensate for reduced dopaminergic tone in the brain.
Label Reference
Section 1 (provided excerpts) does not list Parkinson’s disease; only type 2 diabetes glycemic control indication is provided.
Important Omissions
If the claims are intended to describe CYCLOSET specifically, the FDA label excerpted indication is glycemic control in adults with type 2 diabetes mellitus (adjunct to diet and exercise), including key limitations of use (not for type 1 diabetes/DKA; limited efficacy in combination with thiazolidinediones; efficacy not confirmed with insulin).
Importance:
Moderate
Dose and administration specifics for CYCLOSET (timed once-daily within two hours after waking, with food; titration; missed dose instructions; do not double; dose limits with CYP3A4 inhibitors).
Importance:
Moderate
Key warnings/precautions relevant to CYCLOSET dosing and safety (e.g., hypotension/orthostatic hypotension with orthostatic vitals monitoring; psychotic disorders not recommended; impulse control/compulsive behaviors; somnolence; not recommended with dopamine receptor antagonists; contraindication in postpartum/lactation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims attribute indications (hyperprolactinemia-related disorders; Parkinson’s disease) and prolactin-related symptom benefits that are not supported by the provided CYCLOSET label excerpts, which could mislead on approved uses. Some safety-related content is partially aligned (orthostatic hypotension, dizziness, nausea) but the overall set of claims is largely unsupported relative to the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (indications for hyperprolactinemia and Parkinson’s, prolactin suppression and related symptom benefits, and general 'dopamine-like effects') are not supported by the supplied FDA label excerpts for CYCLOSET.
Suggested Improvement
Restrict statements to the supplied CYCLOSET label excerpts: indication for glycemic control in adults with type 2 diabetes (adjunct to diet and exercise) and mechanism excerpt that bromocriptine mesylate is a dopamine D2 receptor agonist; align safety statements to the specific warnings/adverse reactions provided (e.g., hypotension/orthostatic hypotension, syncope, dizziness, nausea) and avoid unsupported indications/mechanistic claims (prolactin/pituitary cell actions, hyperprolactinemia treatments, Parkinson’s disease).